APPA
phase 2Develop an investigational oral therapy for osteoarthritis and other inflammatory diseases of ageing by modulating inflammatory, oxidative-stress, and senescence-related pathways rather than broadly suppressing immune response.
Fixed-dose oral combination of apocynin and paeonol; evaluated in a randomized, double-blind, placebo-controlled phase 2a knee osteoarthritis trial and in human chondrocyte/neutrophil inflammatory and senescence assays.
2025 publications reported senotherapeutic effects of APPA in senescent human chondrocytes; the prior phase 2a knee osteoarthritis trial found no significant overall WOMAC pain benefit but suggested possible subgroup effects in nociplastic pain/severe OA.
APPA was reported to reduce senescence markers and show senomorphic/senolytic-like activity in senescent chondrocytes. In the phase 2a knee OA trial, APPA 800 mg twice daily for 28 days was safe and well tolerated but did not significantly improve primary WOMAC pain versus placebo overall; pre-planned subgroup analyses suggested benefit in subjects with nociplastic pain/severe OA.